Risk factors for development of atypical femoral fractures in patients on long-term oral bisphosphonate therapy

Bone

Volumn 56, Issue 2, 2013, Pages 426-431

  Franceschetti, Paola ^a   Bondanelli, Marta ^a   Caruso, Gaetano ^a   Ambrosio, Maria Rosaria ^a   Lorusso, Vincenzo ^a   Zatelli, Maria Chiara ^a   Massari, Leo ^a   degli Uberti, Ettore C ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

Atypical femoral fractures; Bisphosphonate; Hypocalcemia; Hypoparathyroidsm

Indexed keywords

25 HYDROXYVITAMIN D; ALENDRONIC ACID; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; GLUCOCORTICOID; IBANDRONIC ACID; LEVOTHYROXINE; PARATHYROID HORMONE; PROTON PUMP INHIBITOR; STRONTIUM RANELATE; THIAMAZOLE; THYROXINE; VITAMIN D;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ATYPICAL FEMORAL FRACTURE; ATYPICAL FEMORAL FRACTURES; BODY MASS; BONE TURNOVER; CALCIUM BLOOD LEVEL; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG USE; FEMALE; FEMUR FRACTURE; HUMAN; HYPERTHYROIDISM; HYPOCALCEMIA; HYPOTHYROIDISM; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MENOPAUSE; OBESITY; OSTEOPENIA; OSTEOPOROSIS; PARATHYROID HORMONE BLOOD LEVEL; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION; TYPICAL FEMORAL FRACTURE; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY;

ATYPICAL FEMORAL FRACTURES; BISPHOSPHONATE; HYPOCALCEMIA; HYPOPARATHYROIDSM;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; FEMORAL FRACTURES; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS;

EID: 84881233587     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2013.07.010     Document Type: Article

References (34)

1. Watts N.B., Diab D.L. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 2010, 95:1555-1565.
2. Schwartz A.V., Bauer D.C., Cummings S.R., Cauley J.A., Ensrud K.E., Palermo L., et al. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res 2010, 25:976-982.
3. Bilezikian J.P. Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. Am J Med 2009, 22:S14-S21.
4. Paccou J., Confavreux C.B., David C., Leboime A., Mehsen N., Cortet B. Stabilized severe osteoporosis: should the treatment be stopped?. Joint Bone Spine 2010, 77:S120-S127.
5. Shane E., Burr D., Ebeling P.R., Abrahamsen B., Adler R.A., Brown T.D., et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010, 25:2267-2294.
6. Rizzoli R., Akesson K., Bouxsein M., Kanis J.A., Napoli N., Papapoulos S., et al. Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int 2011, 22:373-390.
7. Shane E., Ebeling P.R., Abrahamsen B., Adler R.A., Brown T.D., Cheung A.M., et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res May 28 2013, [Epub ahead of print]. 10.1002/jbmr.1998.
8. Bondanelli M., Ambrosio M.R., Carli A., Bergonzoni A., Bertocchi A., Zatelli M.C., et al. Predictors of pituitary dysfunction in patients surviving ischemic stroke. J Clin Endocrinol Metab 2010, 95:4660-4668.
9. Bondanelli M., Ambrosio M.R., Onofri A., Bergonzoni A., Lavezzi S., Zatelli M.C., et al. Predictive value of circulating insulin-like growth factor I levels in ischemic stroke outcome. J Clin Endocrinol Metab 2006, 91:3928-3934.
10. Bondanelli M., Ambrosio M.R., Cavazzini L., Bertocchi A., Zatelli M.C., Carli A., et al. Anterior pituitary function may predict functional and cognitive outcome in patients with traumatic brain injury undergoing rehabilitation. J Neurotrauma 2007, 24:1687-1697.
11. Schilcher J., Koeppen V., Ranstam J., Skripitz R., Michaëlsson K., Aspenberg P. Atypical femoral fractures are a separate entity, characterized by highly specific radiographic features. A comparison of 59 cases and 218 controls. Bone 2013, 52:389-392.
12. Giusti A., Hamdy N.A., Dekkers O.M., Ramautar S.R., Dijkstra S., Papapoulos S.E. Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features. Bone 2011, 48:966-971.
13. Havelka S., Bartůnková V., Streda A. Bone indexes and cortical thickness in assessing osteoporosis in rheumatic patients. Scand J Rheumatol 1973, 2:57-60.
14. Giusti A., Hamdy N.A., Papapoulos S.E. Atypical fractures of the femur and bisphosphonate therapy. A systematic review of case/case series studies. Bone 2010, 47:169-180.
15. Gallagher J.C. Effect of early menopause on bone mineral density and fractures. Menopause 2007, 14:567-571.
16. Svejme O., Ahlborg H.G., Nilsson J.A., Karlsson M.K. Low BMD is an independent predictor of fracture and early menopause of mortality in post-menopausal women-a 34-year prospective study. Maturitas 2013, 74:341-345.
17. Ettinger B., Burr D.B., Ritchie R.O. Proposed pathogenesis for atypical femoral fractures: lessons from material research. Bone 2013, 55:495-500.
18. Unnanuntana A., Saleh A., Mensah K.A., Kleimeyer J.P., Lane J.M. Atypical femoral fractures: what do we know about them?: AAOS exhibit selection. J Bone Joint Surg Am 2013, 95(e8):1-13.
19. Compston J. Obesity and bone. Curr Osteoporos Rep 2013, 11:30-35.
20. Maalouf N.M., Heller H.J., Odvina C.V., Kim P.J., Sakhaee K. Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature. Endocr Pract 2006, 12:48-53.
21. Lenart B.A., Neviaser A.S., Lyman S., Chang C.C., Edobor-Osula F., Steele B., et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 2009, 20:1353-1362.
22. La Rocca Vieira R., Rosenberg Z.S., Allison M.B., Im S.A., Babb J., Peck V. Frequency of incomplete atypical femoral fractures in asymptomatic patients on long-term bisphosphonate therapy. Am J Roentgenol 2012, 198:1144-1151.
23. Tanimoto K., Okubo Y., Harada C., Saito H., Sata A., Nishikawa A., et al. Latent hypoparathyroidism in an osteoporotic patient with multiple endocrinopathies and secondary hemochromatosis due to multiple blood transfusions, unmasked by alendronate and glucocorticoid at adrenal crisis. Intern Med 2008, 47:515-520.
24. Markman L.H., Allison M.B., Rosenberg Z.S., Vieira R.L., Babb J.S., Tejwani N.C., et al. A retrospective review of patients with atypical femoral fractures while on long-term bisphosphonates: including pertinent biochemical and imaging studies. Endocr Pract 2013, 21:1-23.
25. Seeman E. To stop or not to stop, that is the question. Osteoporos Int 2009, 20:187-195.
26. Whitaker M., Guo J., Kehoe T., Benson G. Bisphosphonates for osteoporosis-where do we go from here?. N Engl J Med 2012, 366:2048-2051.
27. Jamal S.A., Dion N., Ste-Marie L.G. Atypical femoral fractures and bone turnover. N Engl J Med 2011, 365:1261-1262.
28. Feldstein A.C., Black D., Perrin N., Rosales A.G., Friess D., Boardman D., et al. Incidence and demography of femur fractures with and without atypical features. J Bone Miner Res 2012, 27:977-986.
29. Allen M.R., Burr D.B. Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: what we think we know and what we know that we don't know. Bone 2011, 49:56-65.
30. Singer F.R. Metabolic bone disease: atypical femoral fractures. J Biomech 2011, 44:244-247.
31. Bondanelli M., Zatelli M.C., Ambrosio M.R., degli Uberti E.C. Systemic illness. Pituitary 2008, 11:187-207.
32. Gunawardena I., Baxter M., Rasekh Y. Bisphosphonate-related subtrochanteric femoral fractures. Am J Geriatr Pharmacother 2011, 9:194-198.
33. Edwards M.H., McCrae F.C., Young-Min S.A. Alendronate-related femoral diaphysis fracture-what should be done to predict and prevent subsequent fracture of the contralateral side?. Osteoporos Int 2010, 21:701-703.
34. Prasarn M.L., Ahn J., Helfet D.L., Lane J.M., Lorich D.G. Bisphosphonate-associated femur fractures have high complication rates with operative fixation. Clin Orthop Relat Res 2012, 470:2295-2301.